Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Effect of Cisplatin on the Frequency and Immuno-inhibitory Function of Myeloid-derived Suppressor Cells in A375 Melanoma Model

  • Huang, Xiang (Department of Oncology, The First Affiliated Hospital of Nanjing Medical University) ;
  • Guan, Dan (Department of Oncology, The First Affiliated Hospital of Nanjing Medical University) ;
  • Shu, Yong-Qian (Department of Oncology, The First Affiliated Hospital of Nanjing Medical University) ;
  • Liu, Lian-Ke (Department of Oncology, The First Affiliated Hospital of Nanjing Medical University) ;
  • Ni, Fang (Department of Laboratory Medicine, The First Affiliated Hospital of Nanjing Medical University)
  • Published : 2015.06.03
Download PDF
⟨ Previous Next ⟩

Abstract

Background: To investigate the change of frequency and immuno-inhibitory function of myeloid-derived suppressor cells (MDSCs) after treatment of cisplatin (DDP) in A375 human melanoma model. Materials and Methods: BALB/c nude mice were inoculated with A375 cells to establish the human melanoma model and randomly divided into control group given normal saline (NS) and experimental group treated with DDP (5 mg/kg). The percentages of MDSCs in the tumor tissue and peripheral blood after DDP treatment were detected by flow cytometry. The proliferation and interferon-${\gamma}$ (IFN-${\gamma}$) secretion of T cells co-cultured with MDSCs were analyzed through carboxyfluorescein succinimidyl ester (CFSE) labeling assay and enzyme-linked immunospot (ELISPOT) assay, respectively. Results: In A375 human melanoma model, DDP treatment could significantly decrease the percentage of MDSCs in the tumor tissue, but exerted no effect on the level of MDSCs in peripheral blood. Moreover, DDP treatment could attenuate the immuno-inhibitory function of MDSCs. T cells co-cultured with DDP-treated MDSCs could dramatically elevate the proliferation and production of INF-${\gamma}$. Conclusions: DDP can decrease the frequency and attenuate immuno-inhibitory function of MDSCs in A375 melanoma model, suggesting a potential strategy to augment the efficacy of combined immunotherapy.

Keywords

References

  1. Alizadeh D, Larmonier N (2014a). Chemotherapeutic targeting of cancer-induced immunosuppressive cells. Cancer Res, 74, 2663-8. https://doi.org/10.1158/0008-5472.CAN-14-0301
  2. Alizadeh D, Katsanis E, Larmonier N (2014b). Chemotherapeutic targeting of myeloid-derived suppressor cells. Oncoimmunol, 3, 27359. https://doi.org/10.4161/onci.27359
  3. Anagnostou VK, Brahmer JR (2015). Cancer immunotherapy: a future paradigm shift in the treatment of non-small cell lung cancer. Clin Cancer Res, 21, 976-84. https://doi.org/10.1158/1078-0432.CCR-14-1187
  4. Chen J, Huang X, Huang G, et al (2012). Preconditioning chemotherapy with cisplatin enhances the antitumor activity of cytokine-induced killer cells in a murine melanoma model. Cancer Biother Radiopharm, 27, 210-20. https://doi.org/10.1089/cbr.2011.1116
  5. Crook KR, Liu P (2014). Role of myeloid-derived suppressor cells in autoimmune disease. World J Immunol, 4, 26-33. https://doi.org/10.5411/wji.v4.i1.26
  6. Curti BD, Urba WJ (2015). Clinical deployment of antibodies for treatment of melanoma. Mol Immunol, [Epub ahead of print].
  7. Fernandez A, Oliver L, Alvarez R, et al (2014). Adjuvants and myeloid-derived suppressor cells: enemies or allies in therapeutic cancer vaccination. Hum Vaccin Immunother, 10, 3251-60. https://doi.org/10.4161/hv.29847
  8. Gabrilovich DI, Nagaraj S (2009). Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol, 9, 162-74. https://doi.org/10.1038/nri2506
  9. Medina-Echeverz J, Ma C, Duffy A, et al (2015). Systemic agonistic anti-CD40 treatment of tumor bearing mice modulates hepatic myeloid suppressive cells and causes immune-mediated liver damage. Cancer Immunol Res, [Epub ahead of print].
  10. Ostrand-Rosenberg S (2010). Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol Immunother, 59, 1593-600. https://doi.org/10.1007/s00262-010-0855-8
  11. Salem ML, Diaz-Montero CM, Al-Khami AA, et al (2009). Recovery from cyclophosphamide-induced lymphopenia results in expansion of immature dendritic cells which can mediate enhanced prime-boost vaccination antitumor responses in vivo when stimulated with the TLR3 agonist poly (I:C). J Immunol, 182, 2030-40. https://doi.org/10.4049/jimmunol.0801829
  12. Shekarian T, Valsesia-Wittmann S, Caux C, et al (2015). Paradigm shift in oncology: targeting the immune system rather than cancer cells. Mutagenesis, 30, 205-11. https://doi.org/10.1093/mutage/geu073
  13. Suzuki E, Kapoor V, Jassar AS, et al (2005). Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res, 11, 6713-21. https://doi.org/10.1158/1078-0432.CCR-05-0883
  14. Swaika A, Hammond WA, Joseph RW (2015). Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy. Mol Immunol, [Epub ahead of print].
  15. Su S, Zhou H, Xue M, et al (2013). Anti-tumor efficacy of a hepatocellular carcinoma vaccine based on dendritic cells combined with tumor-derived autophagosomes in murine models. Asian Pac J Cancer Prev, 14, 3109-16. https://doi.org/10.7314/APJCP.2013.14.5.3109
  16. Umansky V, Sevko A (2013). Tumor microenvironment and myeloid-derived suppressor cells. Cancer Microenviron, 6, 169-77. https://doi.org/10.1007/s12307-012-0126-7
  17. Vincent J, Mignot G, Chalmin F, et al (2010). 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res, 70, 3052-61. https://doi.org/10.1158/0008-5472.CAN-09-3690
  18. Wang WJ, Qin SH, Zhang JW, et al (2014). Combination doxorubicin and interferon-α therapy stimulates immunogenicity of murine pancreatic cancer Panc02 cells via up-regulation of NKG2D ligands and MHC class I. Asian Pac J Cancer Prev, 15, 9667-72. https://doi.org/10.7314/APJCP.2014.15.22.9667
  19. Zhang QM, Shen N, Xie S, et al (2014). MAGED4 expression in glioma and upregulation in glioma cell lines with 5-aza-2'-deoxycytidine treatment. Asian Pac J Cancer Prev, 15, 3495-501. https://doi.org/10.7314/APJCP.2014.15.8.3495
  20. Zheng Y, Dou Y, Duan L, et al (2015). Using chemo-drugs or irradiation to break immune tolerance and facilitate immunotherapy in solid cancer. Cell Immunol, 294, 54-9. https://doi.org/10.1016/j.cellimm.2015.02.003